Spire Wealth Management Sells 5,159 Shares of Harrow Health, Inc. (NASDAQ:HROW)

Spire Wealth Management lowered its stake in shares of Harrow Health, Inc. (NASDAQ:HROWFree Report) by 55.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,170 shares of the company’s stock after selling 5,159 shares during the period. Spire Wealth Management’s holdings in Harrow Health were worth $60,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of HROW. Envestnet Asset Management Inc. purchased a new stake in shares of Harrow Health during the 1st quarter worth approximately $70,000. BlackRock Inc. grew its stake in Harrow Health by 1.2% in the 1st quarter. BlackRock Inc. now owns 436,528 shares of the company’s stock valued at $2,978,000 after buying an additional 5,261 shares in the last quarter. Wasatch Advisors Inc. grew its stake in Harrow Health by 11.2% in the 1st quarter. Wasatch Advisors Inc. now owns 740,104 shares of the company’s stock valued at $5,048,000 after buying an additional 74,800 shares in the last quarter. Prelude Capital Management LLC grew its stake in Harrow Health by 34.4% in the 1st quarter. Prelude Capital Management LLC now owns 94,911 shares of the company’s stock valued at $647,000 after buying an additional 24,293 shares in the last quarter. Finally, State Street Corp grew its stake in Harrow Health by 5.5% in the 1st quarter. State Street Corp now owns 86,813 shares of the company’s stock valued at $592,000 after buying an additional 4,521 shares in the last quarter. Hedge funds and other institutional investors own 75.75% of the company’s stock.

Insider Buying and Selling at Harrow Health

In other news, CEO Mark L. Baum purchased 7,500 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was purchased at an average cost of $8.11 per share, with a total value of $60,825.00. Following the acquisition, the chief executive officer now directly owns 2,022,961 shares in the company, valued at $16,406,213.71. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 13.60% of the company’s stock.

Harrow Health Price Performance

Shares of NASDAQ:HROW opened at $10.80 on Monday. The firm has a fifty day moving average price of $10.10 and a two-hundred day moving average price of $13.06. The company has a debt-to-equity ratio of 2.42, a current ratio of 5.80 and a quick ratio of 5.33. Harrow Health, Inc. has a one year low of $7.60 and a one year high of $28.25.

Harrow Health (NASDAQ:HROWGet Free Report) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Harrow Health had a negative net margin of 12.44% and a negative return on equity of 6.55%. The firm had revenue of $34.27 million during the quarter, compared to the consensus estimate of $37.58 million. During the same period in the previous year, the business earned ($0.06) earnings per share. The firm’s revenue for the quarter was up 50.1% on a year-over-year basis. As a group, equities analysts anticipate that Harrow Health, Inc. will post -0.43 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, TheStreet lowered shares of Harrow Health from a “c-” rating to a “d+” rating in a research note on Tuesday, December 12th.

Get Our Latest Analysis on Harrow Health

About Harrow Health

(Free Report)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Further Reading

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow Health, Inc. (NASDAQ:HROWFree Report).

Institutional Ownership by Quarter for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.